The blood-brain barrier (BBB) blocks the development of biologic pharmaceuticals for the brain.

ArmaGen® provides platform technology solutions to the blood-brain barrier problem and can non-invasively target recombinant proteins, therapeutic monoclonal antibodies, and siRNA to the brain.